A specialist from Oman, located at the crossroads of Africa and Asia, explains that his nation serves as a microcosm when it ...

Turkish immigrant Oguzhan Atay started the company in 2016 with a focus on prenatal testing. Now, he’s expanding to cancer ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

said Joanne Lager, MD, Chief Medical Officer. "The presentation highlights the growing demand for ZYNTEGLO, the first FDA-approved gene therapy for eligible patients with transfusion-dependent ...

A new research project at the Cyprus Institute of Neurology and Genetics (CING) aims to develop a one-time, curative therapy for beta-thalassaemia, the most common inherited blood disorder in Cyprus.

Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin ...

Traditional medications are synthesized through chemical reactions, whereas biologics are derived from and reproduced, at ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that ...